NASDAQ : OTLK

Outlook Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 0.4935 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 120.14M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Details

NameOutlook Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees17
Founded2010
Ipo Date2016-05-13
CeoRobert Jahr
CountryUnited States
ExchangeNASDAQ
Fiscal YearOctober - September
Reporting CurrencyUSD
IsinUS69012T3059
Cusip69012T305
Cik0001649989
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Robert Charles JahrPresident, Chief Executive Officer and Director
Kevin LundquistChief Financial Officer, Treasurer, Principal Financial Officer and Principal Accounting Officer
Joel PrieveSenior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs
Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development and Regulatory Affairs
Jedd ComiskeySenior Vice President - Head of Europe

Contact

Address111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830, United States
Phone609 619 3990
Websitehttps://outlooktherapeutics.com